ChemicalBook
Chinese Japanese Germany

Dideoxyinosine

Dideoxyinosine
Dideoxyinosine
CAS No.
69655-05-6
Chemical Name:
Dideoxyinosine
Synonyms
DDI;ddino;VIDEX;DDLNO;bmy40900;Didansine;nsc612049;2',3'-ddI;DIDANOSINE;2.3-Dideoxy
CBNumber:
CB0680765
Molecular Formula:
C10H12N4O3
Formula Weight:
236.23
MOL File:
69655-05-6.mol

Dideoxyinosine Properties

Melting point:
193-195 °C
Boiling point:
193-195 C
alpha 
D25 -26.3° (c = 10 in water)
Density 
1.2917 (rough estimate)
refractive index 
-28 ° (C=0.34, H2O)
storage temp. 
2-8°C
solubility 
Soluble in DMSO or methanol
form 
Powder
pka
9.12(at 25℃)
color 
White to Off-white
Water Solubility 
1-5 g/100 mL at 21 ºC
Merck 
14,3098
BRN 
3619529
Stability:
Stable. Combustible. Incompatible with strong oxidizing agents.
CAS DataBase Reference
69655-05-6(CAS DataBase Reference)
EPA Substance Registry System
Inosine, 2',3'-dideoxy-(69655-05-6)
SAFETY
  • Risk and Safety Statements
  • Hazard and Precautionary Statements (GHS)
Hazard Codes  C
Risk Statements  34-36/37
Safety Statements  26-27-36/37/39-45-24/25
WGK Germany  2
RTECS  NM7460700
HS Code  29335990
Hazardous Substances Data 69655-05-6(Hazardous Substances Data)
Symbol(GHS):
Signal word: Warning
Hazard statements:
Code Hazard statements Hazard class Category Signal word Pictogram P-Codes
H341 Suspected of causing genetic defects Germ cell mutagenicity Category 2 Warning P201,P202, P281, P308+P313, P405,P501
H373 May cause damage to organs through prolonged or repeated exposure Specific target organ toxicity, repeated exposure Category 2 Warning P260, P314, P501
Precautionary statements:
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe dust/fume/gas/mist/vapours/spray.
P280 Wear protective gloves/protective clothing/eye protection/face protection.
P308+P313 IF exposed or concerned: Get medical advice/attention.
P405 Store locked up.
P501 Dispose of contents/container to..…

Dideoxyinosine price More Price(13)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Sigma-Aldrich D0162 2′,3′-Dideoxyinosine ≥98% (HPLC) 69655-05-6 5mg $172 2018-11-20 Buy
Sigma-Aldrich 1191204 Didanosine United States Pharmacopeia (USP) Reference Standard 69655-05-6 200mg $1678.25 2018-11-20 Buy
TCI Chemical D3066 2',3'-Dideoxyinosine >98.0%(HPLC)(T) 69655-05-6 100mg $40 2018-11-22 Buy
TCI Chemical D3066 2',3'-Dideoxyinosine >98.0%(HPLC)(T) 69655-05-6 500mg $132 2018-11-22 Buy
Alfa Aesar J64833 2',3'-Dideoxyinosine, 98% 69655-05-6 1g $120 2018-11-13 Buy

Dideoxyinosine Chemical Properties,Uses,Production

Chemical Properties

White Powder

Uses

Antiviral;Transrcriptase inverse inhibitor

Uses

Used as an antiviral

Definition

ChEBI: A purine 2',3'-dideoxyribonucleoside that is inosine in which the hydroxy groups at both the 2' and the 3' positions on the sugar moiety have been replaced by hydrogen.

brand name

Videx (Bristol-Myers Squibb).

Antimicrobial activity

Didanosine is active against HIV-1, HIV-2 and HTLV-1.

Acquired resistance

Codon changes at positions 65 or 74 in HIV reverse transcriptase are associated with reduced susceptibility.

General Description

Fluffy white solid or powder. Condenses at 347°F and darkens at approximately 572°F. Odorless.

Air & Water Reactions

Water soluble.

Health Hazard

SYMPTOMS: Symptoms of exposure to a related compound include cutaneous eruptions, fever, mouth sores, thrombocytopenia, neutropenia, reversible peripheral neuropathy, gastrointestinal distress, headache, nausea and vomiting.

Fire Hazard

Flash point data for Dideoxyinosine are not available; however, Dideoxyinosine is probably combustible.

Pharmaceutical Applications

An analog of deoxyadenosine, formulated for oral administration.

Pharmacokinetics

Oral absorption: c. 40%
Cmax 400 mg once daily: 0.93 mg/L
Plasma half-life: c. 1.4 h
Volume of distribution: c. 1 L/kg
Plasma protein binding: <5%
Absorption
Bioavailability is reduced by about half when taken with food and the drug should be given at least 30 min before a meal. The peak plasma concentration achieved by enteric-coated tablets is less than half that of buffered tablets.
Distribution
Central nervous system (CNS) penetration is relatively poor. Median concentrations in semen (455 ng/mL; range < 50–2190 ng/mL) are greater than those in blood (<50 ng/mL; range <50–860 ng/mL). It is secreted in breast milk.
Metabolism
Based upon animal studies it is presumed that metabolism occurs by the pathways responsible for the elimination of endogenous purines by xanthine oxidase. Metabolism may be altered in patients with severe hepatic impairment; however, no specific dose adjustment is recommended.
Excretion
Renal clearance by glomerular filtration and active tubular secretion accounts for 50% of total body clearance. Urinary recovery accounts for about 20% of the oral dose in adults. The half-life increases three-fold in patients requiring dialysis. Patients with a creatinine clearance <60 mL/min may be at greater risk of toxicity.

Clinical Use

Treatment of HIV infection (in combination with other antiretroviral drugs)

Side effects

Most serious are pancreatitis (fatal and non-fatal), lactic acidosis and severe hepatomegaly with steatosis (fatal and nonfatal), retinopathy, optic neuritis and dose-related peripheral neuropathy. Patients with low body weight may require dose modification. A strong association with non-cirrhotic portal hypertension has been described.
The combination with stavudine should be avoided in pregnant women as fatal cases of lactic acidosis have been reported. Caution should also be exercised in patients with known risk factors for liver disease. Therapy should be stopped in patients who develop clinical or laboratory evidence of lactic acidosis or hepatotoxicity. Monitoring lactate levels prospectively is not recommended as mild hyperlactatemia occurs in asymptomatic patients and has a poor positive predictive value for the development of lactic acidosis.
Caution should be exercised in co-administering other drugs with known neurotoxicity and in patients with a history of neuropathy. Treatment should stop if symptoms and signs of neuropathy are observed, but the condition is usually reversible and patients with resolved neuropathy may be retreated at a reduced dosage. Retinal depigmentation has been observed in children and twice-yearly dilated retinal examination is recommended.

Dideoxyinosine Preparation Products And Raw materials

Raw materials

Preparation Products


Dideoxyinosine Suppliers

Global( 212)Suppliers
Supplier Tel Fax Email Country ProdList Advantage
Shenzhen Sendi Biotechnology Co.Ltd.
0755-23311925 18102838259
0755-23311925 Abel@chembj.com CHINA 3217 55
Henan DaKen Chemical CO.,LTD.
+86-371-55531817
info@dakenchem.com CHINA 22049 58
Henan Tianfu Chemical Co.,Ltd.
0371-55170693
0371-55170693 info@tianfuchem.com CHINA 20786 55
Mainchem Co., Ltd.
+86-0592-6210733
+86-0592-6210733 sales@mainchem.com CHINA 32651 55
Shanghai Boyle Chemical Co., Ltd.
86-21-57758967 sales@boylechem.com China 2928 55
J & K SCIENTIFIC LTD. 400-666-7788 +86-10-82848833
+86-10-82849933 jkinfo@jkchemical.com;market6@jkchemical.com China 96815 76
Meryer (Shanghai) Chemical Technology Co., Ltd. +86-(0)21-61259100(Shanghai) +86-(0)755-86170099(ShenZhen) +86-(0)10-62670440(Beijing)
+86-(0)21-61259102(Shanghai) +86-(0)755-86170066(ShenZhen) +86-(0)10-88580358(Beijing) sh@meryer.com China 40395 62
3B Pharmachem (Wuhan) International Co.,Ltd. 86-21-50328103 * 801、802、803、804 Mobile:18930552037
86-21-50328109 3bsc@sina.com China 15926 69
Hongene Biotechnology Limited 86-21-64757213
86-21-64700613 info@hongene.com; sales@hongene.com China 449 61
Chembest Research Laboratories Limited +86(0)21-20908456
+86(0)21-58180499 sales@biochembest.com; market@biochembest.com China 6054 61

69655-05-6(Dideoxyinosine)Related Search:


Copyright 2017 © ChemicalBook. All rights reserved